Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages 532-542

  Ramasamy, Sundaram ^a   Nguyen, Deanna D ^a   Eston, Michelle A ^a   Nasrin Alam, Sayeda ^a   Moss, Angela K ^a   Ebrahimi, Farzad ^a   Biswas, Brishti ^a   Mostafa, Golam ^a   Chen, Kathryn T ^a   Kaliannan, Kanakaraju ^a   Yammine, Halim ^a   Narisawa, Sonoko ^b   Millán, José Luis ^b   Warren, H Shaw ^a   Hohmann, Elizabeth L ^a   Mizoguchi, Emiko ^a   Reinecker, Hans Christian ^a   Bhan, Atul K ^a   Snapper, Scott B ^a   Malo, Madhu S ^a   Hodin, Richard A ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

DSS induced chronic colitis; gut mucosal defense; inflammatory bowel disease; lipopolysaccharides; spontaneous chronic colitis; WASP KO

Indexed keywords

ALKALINE PHOSPHATASE INTESTINE ISOENZYME; CYTOKINE; DRINKING WATER; GASTROINTESTINAL AGENT; MYELOPEROXIDASE; UNCLASSIFIED DRUG; WISKOTT ALDRICH SYNDROME PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC DISEASE; COLITIS; COLON; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; HISTOPATHOLOGY; INTESTINE; IRRADIATION; MICROSCOPIC COLITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SUPPLEMENTATION; WEIGHT REDUCTION; WISKOTT ALDRICH SYNDROME;

ALKALINE PHOSPHATASE; ANIMALS; CHRONIC DISEASE; COLITIS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEROXIDASE; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 78651288687     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21377     Document Type: Article

References (44)

1. Garrett WS, Gordon JI, Glimcher LH,. Homeostasis and inflammation in the intestine. Cell. 2010; 140: 859-870.
2. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434.
3. Soderlund S, Granath F, Brostrom O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010; 138: 1697-1703.
4. Mizoguchi A, Mizoguchi E, Bhan AK,. Immune networks in animal models of inflammatory bowel disease. Inflamm Bowel Dis. 2003; 9: 246-259.
5. Goldberg RF, Austen WG Jr, Zhang X, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci U S A. 2008; 105: 3551-3556.
6. Bates JM, Akerlund J, Mittge E, et al. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe. 2007; 2: 371-382.
7. Tuin A, Poelstra K, de Jager-Krikken A, et al. Role of alkaline phosphatase in colitis in man and rats. Gut. 2009; 58: 379-387.
8. Lukas M, Drastich P, Konecny M, et al. Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. Inflamm Bowel Dis. 2009 [Epub ahead of print].
9. Poelstra K, Bakker WW, Klok PA, et al. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest. 1997; 76: 319-327. (Pubitemid 27157340)
10. Nakano T, Inoue I, Alpers DH, et al. Role of lysophosphatidylcholine in brush-border intestinal alkaline phosphatase release and restoration. Am J Physiol Gastrointest Liver Physiol. 2009; 297: G207-214.
11. Kitajima S, Takuma S, Morimoto M,. Tissue distribution of dextran sulfate sodium (DSS) in the acute phase of murine DSS-induced colitis. J Vet Med Sci. 1999; 61: 67-70.
12. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69: 238-249.
13. Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity. 1998; 9: 81-91.
14. Bouma G, Burns S, Thrasher AJ,. Impaired T-cell priming in vivo resulting from dysfunction of WASp-deficient dendritic cells. Blood. 2007; 110: 4278-4284.
15. Maillard MH, Cotta-de-Almeida V, Takeshima F, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med. 2007; 204: 381-391.
16. Adriani M, Aoki J, Horai R, et al. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin Immunol. 2007; 124: 41-48.
17. Humblet-Baron S, Sather B, Anover S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest. 2007; 117: 407-418.
18. Marangoni F, Trifari S, Scaramuzza S, et al. WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J Exp Med. 2007; 204: 369-380.
19. Snapper SB, Meelu P, Nguyen D, et al. WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo. J Leukoc Biol. 2005; 77: 993-998.
20. Zicha D, Allen WE, Brickell PM, et al. Chemotaxis of macrophages is abolished in the Wiskott-Aldrich syndrome. Br J Haematol. 1998; 101: 659-665.
21. Nguyen DD, Maillard MH, Cotta-de-Almeida V, et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology. 2007; 133: 1188-1197.
22. Narisawa S, Huang L, Iwasaki A, et al. Accelerated fat absorption in intestinal alkaline phosphatase knockout mice. Mol Cell Biol. 2003; 23: 7525-7530.
23. Klein C, Nguyen D, Liu CH, et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood. 2003; 101: 2159-2166.
24. Krieglstein CF, Anthoni C, Cerwinka WH, et al. Role of blood- and tissue-associated inducible nitric-oxide synthase in colonic inflammation. Am J Pathol. 2007; 170: 490-496.
25. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002; 109: 883-893.
26. Siegmund B, Lehr HA, Fantuzzi G, et al. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A. 2001; 98: 13249-13254.
27. Krawisz JE, Sharon P, Stenson WF,. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984; 87: 1344-1350.
28. Wang X, Wang J, Wong SC, et al. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci. 2000; 67: 2663-2671.
29. Alex P, Zachos NC, Nguyen T, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009; 15: 341-352.
30. Podolsky DK,. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417-429.
31. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995; 182: 1281-1290.
32. Hsieh KH, Chang MH, Lee CY, et al. Wiskott-Aldrich syndrome and inflammatory bowel disease. Ann Allergy. 1988; 60: 429-431.
33. Folwaczny C, Ruelfs C, Walther J, et al. Ulcerative colitis in a patient with Wiskott-Aldrich syndrome. Endoscopy. 2002; 34: 840-841.
34. Chen KT, Malo S, Moss A, et al. Identification of specific targets for the gut mucosal defense factor intestinal alkaline phosphatase. Am J Physiol Gastrointest Liver Physiol. 2010 (in press).
35. Kelly-Wintenberg K, South SL, Montie TC,. Tyrosine phosphate in a- and b-type flagellins of Pseudomonas aeruginosa. J Bacteriol. 1993; 175: 2458-2461.
36. Obermeier F, Dunger N, Deml L, et al. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol. 2002; 32: 2084-2092.
37. Alpers DH, Zhang Y, Ahnen DJ,. Synthesis and parallel secretion of rat intestinal alkaline phosphatase and a surfactant-like particle protein. Am J Physiol Endocrinol Metab. 1995; 268: E1205-1214.
38. McConnell RE, Higginbotham JN, Shifrin DA Jr, et al. The enterocyte microvillus is a vesicle-generating organelle. J Cell Biol. 2009; 185: 1285-1298.
39. Hudcovic T, Stepankova R, Cebra J, et al. The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice. Folia Microbiol (Praha). 2001; 46: 565-572.
40. Rojas-Cartagena C, Flores I, Appleyard CB,. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine. 2005; 32: 85-93.
41. Dharmani P, Chadee K,. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key. Curr Mol Pharmacol. 2008; 1: 195-212.
42. Ogata H, Hibi T,. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des. 2003; 9: 1107-1113.
43. Rabe B, Chalaris A, May U, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008; 111: 1021-1028.
44. Rose-John S, Waetzig GH, Scheller J, et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 2007; 11: 613-624.